Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

849

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

July 31, 2027

Conditions
Breast Carcinoma
Interventions
BIOLOGICAL

eftilagimod alpha

APC activator, MHC II agonist

DRUG

Paclitaxel

paclitaxel will be given as standard of care (chemotherapy)

OTHER

placebo

placebo matching eftilagimod alpha

Trial Locations (22)

1200

Cliniques Universitaires Saint-Luc, Brussels

2025

ARENSIA Exploratory Medicine Phase I Unit, Chisinau

2650

Universitair Ziekenhuizen Antwerpen, Edegem

6000

Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi

6800

Centre Hospitalier de l'Ardenne, Libramont

14004

Hospital Universitario Reina Sofia, Córdoba

20037

The George Washington University Cancer Center, Washington D.C.

23007

Hospital Universitario de Jaén, Jaén

25196

Unidad Ensayos Clínicos Oncología Fundació IRB Lleida, Lleida

28040

START Madrid - FJD, Hospital Fundación Jiménez Diaz, Madrid

28046

Hospital Universitario La Paz, Madrid

29723

Carolina Blood and Cancer Care Associates, Rock Hill

77024

Oncology Consultants, Houston

77030

The University of Texas MD Anderson Cancer Center, Houston

90602

The Oncology Institute, Whittier

Unknown

AZ Sint-Jan Brugge Oostende av, Bruges

Clinique Saint-Pierre- Ottignies, Ottignies-Louvain-la-Neuve

ARENSIA Exploratory Medicine LLC, Tbilisi

08916

Institut Català d'Oncologia, Badalona

08035

VHIO - Hospital Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

08208

Parc Taulí Hospital Universitari, Barcelona

All Listed Sponsors
lead

Immutep S.A.S.

INDUSTRY